Nanoparticle albumin-bound paclitaxel in 3 dosing schedules with bevacizumab as first line therapy for HER2-negative metastatic breast cancer: an interim safety analysis
A.D. Seidman, A.K. Conlin, M.E. Moynahan, A. Bach, T. Troso-Sandoval, S. Sugarman, A. Forero, R. Kerr, G. Wright, C.A. HudisVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)70889-9
File:
PDF, 63 KB
english, 2008